720 related articles for article (PubMed ID: 20621900)
41. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
42. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.
Friedman RJ; Dahl OE; Rosencher N; Caprini JA; Kurth AA; Francis CW; Clemens A; Hantel S; Schnee JM; Eriksson BI;
Thromb Res; 2010 Sep; 126(3):175-82. PubMed ID: 20434759
[TBL] [Abstract][Full Text] [Related]
43. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients.
Lin H; Faraklas I; Saffle J; Cochran A
J Trauma; 2011 Dec; 71(6):1557-61. PubMed ID: 22027887
[TBL] [Abstract][Full Text] [Related]
44. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
[TBL] [Abstract][Full Text] [Related]
45. Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3).
Eriksson BI; Agnelli G; Gallus AS; Lassen MR; Prins MH; Renfurm RW; Kashiwa M; Turpie AG
Thromb Haemost; 2014 Feb; 111(2):213-25. PubMed ID: 24136153
[TBL] [Abstract][Full Text] [Related]
46. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Schulman S; Kakkar AK; Goldhaber SZ; Schellong S; Eriksson H; Mismetti P; Christiansen AV; Friedman J; Le Maulf F; Peter N; Kearon C;
Circulation; 2014 Feb; 129(7):764-72. PubMed ID: 24344086
[TBL] [Abstract][Full Text] [Related]
47. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.
Amin AN; Lin J; Lenhart G; Schulman KL
Thromb Haemost; 2009 Aug; 102(2):321-6. PubMed ID: 19652883
[TBL] [Abstract][Full Text] [Related]
48. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
[TBL] [Abstract][Full Text] [Related]
49. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
Raskob GE; Gallus AS; Pineo GF; Chen D; Ramirez LM; Wright RT; Lassen MR
J Bone Joint Surg Br; 2012 Feb; 94(2):257-64. PubMed ID: 22323697
[TBL] [Abstract][Full Text] [Related]
50. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
Weitz JI; Bauersachs R; Becker B; Berkowitz SD; Freitas MCS; Lassen MR; Metzig C; Raskob GE
JAMA; 2020 Jan; 323(2):130-139. PubMed ID: 31935028
[TBL] [Abstract][Full Text] [Related]
51. Meta-regression analysis to indirectly compare prophylaxis with dalteparin or enoxaparin in patients at high risk for venous thromboembolic events.
Dranitsaris G; Jelincic V; Choe Y
Clin Appl Thromb Hemost; 2012 Jun; 18(3):233-42. PubMed ID: 22387576
[TBL] [Abstract][Full Text] [Related]
52. Safety of fondaparinux in the prevention of venous thromboembolism in elderly medical patients: results of a single-center, retrospective study.
Silvestri F; Pasca S; Labombarda A; Barbi A; Desideri M; Guidi P; Rogato A; Zaramella M; Bergamo M; Ageno W; Barillari G
Minerva Med; 2014 Jun; 105(3):221-8. PubMed ID: 24988087
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and Safety of a Biosimilar Versus Branded Enoxaparin in the Prevention of Venous Thromboembolism Following Major Abdominal Surgery: A Randomized, Prospective, Single-Blinded, Multicenter Clinical Trial.
Ramacciotti E; Ferreira U; Costa AJV; Raymundo SRO; Correa JA; Neto SG; Osvaldt AB; Agati L; Aguiar VCR; Davila R; Caltabiano TB; Magella FM; Volpiani GG; Castelli V; Caffaro RA; DalAcqua LZ; Matheus WE; Sato DY; Russeff GJDS; de Souza DG; Pazetto LE; de Lima TAM; Colnago EMDS; Fugii EY; Mussalem JS; Assao VT; Toffoletto O; Rodrigues DG; Afiune JB; Araujo GR
Clin Appl Thromb Hemost; 2018 Nov; 24(8):1208-1215. PubMed ID: 30021463
[TBL] [Abstract][Full Text] [Related]
54. Prolonged thromboprophylaxis with enoxaparin in early neurological rehabilitation.
Lang A; Kienitz C; Wetzel P; Rollnik JD
Clin Appl Thromb Hemost; 2011 Oct; 17(5):470-5. PubMed ID: 20547551
[TBL] [Abstract][Full Text] [Related]
55. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
[TBL] [Abstract][Full Text] [Related]
56. Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline.
Lederle FA; Zylla D; MacDonald R; Wilt TJ
Ann Intern Med; 2011 Nov; 155(9):602-15. PubMed ID: 22041949
[TBL] [Abstract][Full Text] [Related]
57. Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients.
Ageno W; Spyropoulos AC; Turpie AG
Thromb Haemost; 2012 Jun; 107(6):1027-34. PubMed ID: 22437976
[TBL] [Abstract][Full Text] [Related]
58. Enoxaparin: a review of its use as thromboprophylaxis in acutely ill, nonsurgical patients.
Siddiqui MA; Wagstaff AJ
Drugs; 2005; 65(7):1025-36. PubMed ID: 15892594
[TBL] [Abstract][Full Text] [Related]
59. Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.
Albertsen IE; Larsen TB; Rasmussen LH; Overvad TF; Lip GY
Drugs; 2012 Sep; 72(13):1755-64. PubMed ID: 22876779
[TBL] [Abstract][Full Text] [Related]
60. Relevance of immobility and importance of risk assessment management for medically ill patients.
Hull RD
Clin Appl Thromb Hemost; 2013 Jun; 19(3):268-76. PubMed ID: 22826444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
